Software as a Medical Device Market Size, Share & Industry Analysis, By SaMD Risk Category, By Deployment, By Clinical Function, By Clinical Specialty, By End User, and Regional Forecast, 2026-2034

The global software as a medical device market size was valued at USD 6.64 billion in 2025 and is projected to grow from USD 7.69 billion in 2026 to USD 23.23 billion by 2034, exhibiting a CAGR of 14.8% during the forecast period.

Software as a medical devices (SaMD) refer to standalone software intended for medical purposes, including diagnosis, treatment, or disease monitoring. These devices perform their function without being part of a physical hardware medical device, and can operate on general-purpose computing platforms, such as smartphones and cloud servers. The growing prevalence of chronic conditions, increasing demand for AI-enabled software, technological advancements, and growing healthcare expenditure are resulting in an increasing adoption of these products in the market. The increasing digitalization is further augmenting product adoption.

• For instance, according to the 2025 statistics published by the International Diabetes Federation (IDF), about 6.5 million adults are affected by diabetes in Germany.

Furthermore, the growing focus of key companies, including GE HealthCare and Siemens Healthineers AG, on developing and commercializing innovative SaMD solutions is further contributing to the demand for this software.

Software as a Medical Device Market Trends

Increasing Integration of Artificial Intelligence and Machine Learning in SaMD Platforms

There is an increasing incorporation of Artificial Intelligence (AI) and Machine Learning (ML) into software as a medical device (SaMD) platforms to improve disease diagnosis, clinical decision support, patient monitoring, and treatment planning. AI-enabled software analyzes large volumes of medical images, laboratory results, physiological signals, and other patient data to identify patterns that support faster and more consistent clinical assessment. Furthermore, key companies are also expanding AI-based applications across cardiology, radiology, neurology, gastroenterology, ophthalmology, and other clinical specialties, thereby contributing to increasing authorizations of these devices and fueling their adoption rate.

• For instance, according to 2026 data published by the Food & Drug Administration (FDA), more than 1,600 AI-enabled medical devices were authorized by the U.S. FDA by 2025, demonstrating the rapid commercialization of AI-based medical technologies.

Market Dynamics

Market Drivers

Download Free sample to learn more about this report.

Increasing Prevalence of Chronic Conditions to Drive Market Growth

The growing prevalence of chronic diseases, including cardiovascular diseases and diabetes, is anticipated to increase the need for continuous and remote patient monitoring solutions globally, further resulting in growing product adoption. SaMD solutions support the monitoring of parameters including blood glucose, blood pressure, heart rhythm, respiratory function, and other disease-specific indicators through integration with connected medical devices and digital health platforms.

• For instance, according to 2024 data published by the Centers for Disease Control and Prevention (CDC), about 1 in 20 adults aged 20 and older have coronary artery disease.

Therefore, the factors above, along with the increasing emphasis of key companies on offering advanced products, are further anticipated to bolster the global software as a medical device market growth.

Market Restraints

High Cost of Software Development, Validation, and Lifecycle Maintenance to Hamper the Market Growth

High cost associated with the development, validation, and maintenance of SaMD solutions is expected to hamper market growth, especially for start-ups and small digital health companies. SaMD products must undergo extensive software verification and validation, clinical evaluation, risk management, cybersecurity assessment, quality-management procedures, and regulatory review before commercialization. These requirements can significantly increase development timelines and cost, thereby hampering market growth.

• For instance, according to the 2025 data, the U.S. FDA charges a standard fee of USD 26,067 for a 510(k) submission, illustrating the regulatory expense associated with bringing eligible medical-device software to market.

Market Opportunities

Expansion of Healthcare Infrastructure to Create Lucrative Opportunities

The continued expansion and digitalization of healthcare infrastructure across developed and developing countries is anticipated to create lucrative opportunities in the market. Governmental organizations are focusing on investment in healthcare facilities, including primary-care facilities, hospitals, digital health records, health information exchanges, telemedicine networks, and broadband connectivity to enhance accessibility and efficiency. These developments offer the technological foundation required for the deployment of SaMD devices across monitoring, diagnostic, and clinical decision-support applications. Increasing advancements in healthcare infrastructure, coupled with growing healthcare spending, is contributing to boosting demand for these services in the market.

• According to 2025 data published by the International Trade Administration (ITA), healthcare spending is USD 135.0 billion in Brazil.

Market Challenges

Limited Availability of Advanced Devices in Developing Countries to Hinder Market Growth

The limited availability of advanced medical devices and digital infrastructure in emerging markets is expected to hamper the adoption of software as a medical device (SaMD). SaMD solutions, especially those used for physiological monitoring, diagnostic imaging, clinical decision support, and remote patient monitoring, depend on data generated by connected medical equipment, wearable devices, smartphones, and hospital information systems. Limited access to these innovative technologies and an insufficient number of healthcare facilities therefore hamper the adoption rate for advanced software-based medical applications.

• For instance, according to the 2026 data published by International Citizens Insurance (ICI), it was reported that there are only 600 hospitals in South Africa.

SEGMENTATION ANALYSIS

By SaMD Risk Category

Increasing Prevalence of Acute Conditions Led to the Category II Segmental Dominance

Based on the SaMD risk category, the market is classified into category I, category II, category III, and category IV.

To know how our report can help streamline your business, Speak to Analyst

The category II segment held the largest revenue share in 2025. The growth is due to the increasing prevalence of acute diseases resulting in a growing demand for SaMD products among the patient population. This, along with the increasing number of key companies providing novel software, is further anticipated to contribute to the segment growth.

• For instance, according to 2021 data published by the National Institute of Mental Health (NIMH), an estimated 21.0 million adults had at least one major depressive episode in the U.S.

The category III segment is expected to grow at a CAGR of 15.8% over the forecast period.

By Deployment

Increasing Demand for FDA-Regulated Software Led to the Dominance of the Cloud-based Segment

Based on the deployment, the market is segmented into cloud-based, on-premise, and hybrid.

The cloud-based segment dominated the global market in 2025. By deployment, the cloud-based segment held a share of 54.7% in 2025. The growth is due to the increasing demand for FDA-regulated software, resulting in an increasing adoption of cloud-based software, thereby contributing to the segmental growth in the market.

• For instance, according to the 2023 data published by the Office of the National Coordinator for Health Information Technology (ONCHIT), nine in ten hospitals used application programming interfaces to enable apps to grant patient access to EHR data.

The on-premise segment is set to flourish at a CAGR of 9.3% over the forecast period.

By Clinical Function

Rising Authorization for Diagnosis Devices Led to the Dominance of the Diagnosis & Detection Segment

Based on the clinical function, the market is segmented into diagnosis & detection, monitoring, treatment planning & clinical decision support, and others.

The diagnosis & detection segment dominated the global market in 2025. By clinical function, the diagnosis & detection segment held a share of 40.1% in 2025. The growth is due to the increasing regulatory authorizations for diagnosis devices, resulting in growing adoption of this software, thereby contributing to the segmental growth in the market.

• For instance, according to 2025 data published by the JAMA Network, a total of 950 AI/ML devices were authorized by the FDA, of which 723 were radiology devices (76%).

The monitoring segment is set to flourish with a growth rate of 15.3% across the forecast period.

By Clinical Specialty

Growing Disease Burden for Cancer Led to the Dominance of the Others Segment

Based on the clinical specialty, the market is segmented into cardiology, neurology, ophthalmology, mental & behavioral health, and others.

The others segment dominated the global market in 2025. By clinical specialty, the others segment held a share of 29.5% in 2025. The growth is due to the increasing prevalence of chronic diseases, including cancer, resulting in growing adoption of this software, thereby contributing to the segmental growth in the market.

• For instance, according to 2026 data published by the National Institutes of Health (NIH), approximately 2.1 million new cancer cases are projected to occur in the U.S.

The cardiology segment is set to flourish with a growth rate of 15.1% across the forecast period.

By End User

Hospitals & Health Systems Dominated due to a Rise in the Number of these Settings

Based on end user, the market is divided into hospitals & health systems, diagnostic centers & laboratories, specialty clinics & ambulatory centers, homecare settings, and others.

The hospitals & health systems segment dominated the market in 2025. The increasing number of hospitals, high volume of patient admissions, and increasing adoption of digital devices are some of the crucial factors contributing to the growth of the segment in the market. Furthermore, the segment is set to hold a 46.9% share in 2026.

• For instance, according to 2025 data published by Bundesministerium für Gesundheit, it was reported that there are over 1,800 hospitals in Germany.

In addition, the diagnostic centers & laboratories segment is projected to grow at a CAGR of 14.2% during the forecast period.

Software as a Medical Device Market Regional Outlook

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

The North America market held the dominant share in 2024, valued at USD 2.61 billion, and maintained the leading share in 2025, with a value of USD 3.01 billion. The increasing prevalence of chronic conditions and rising product authorizations are some of the crucial factors contributing to the growth of the segment in the market.

• For instance, in November 2025, Koninklijke Philips N.V., received U.S. FDA 510(k) approval for its Cardiovascular Workspace (IntelliSpace Cardiovascular, ISCV), a cardiovascular imaging and information management solution.

U.S. Software as a Medical Device Market

Based on North America’s strong contribution and the U.S. dominance within the region, the U.S. market can be analytically approximated at around USD 3.19 billion in 2026, accounting for roughly 41.5% of global sales.

Europe

Europe is projected to record a CAGR of 13.1% over the forecast period, which is the second highest among all regions, and reach a valuation of USD 1.96 billion by 2026. The growing prevalence of chronic conditions among patients is expected to contribute to the market growth.

U.K. Software as a Medical Device Market

The U.K. market is estimated at around USD 0.36 billion in 2026, representing roughly 4.7% of global revenues.

Germany Software as a Medical Device Market

The Germany market is projected to reach approximately USD 0.44 billion in 2026, equivalent to around 5.7% of global sales.

Asia Pacific

Asia Pacific is estimated to reach USD 1.78 billion in 2026 and secure the position of the third-largest region in the market. Increasing healthcare access and adoption of digital tools are likely to support the growth of the market.

Japan Software as a Medical Device Market

The Japan market is estimated at around USD 0.46 billion in 2026, accounting for roughly 6.0% of global revenues. Compared to other countries in the region, Japan has historically reported relatively high adoption of clinical decision support software.

China Software as a Medical Device Market

The China market is projected to reach approximately USD 0.46 billion in 2026, representing roughly 5.9% of global sales.

India Software as a Medical Device Market

The India market size is estimated at around USD 0.16 billion in 2026, accounting for roughly 2.1% of global revenues.

Latin America and the Middle East & Africa

Latin America and the Middle East & Africa regions are expected to witness moderate growth during the forecast period. The Latin America market is set to reach a valuation of USD 0.29 billion in 2026.  The growth is due to the increasing demand for healthcare AI and medical imaging software, among others, in the region. The Middle East & Africa is also expected to grow at a considerable rate due to the growing demand for digital therapeutics and the introduction of healthcare software, including AI-powered medical software and diagnostic software among the key companies in the market. In the Middle East & Africa, the GCC is set to reach a value of USD 0.10 billion in 2026.

South Africa Software as a Medical Device Market

The South Africa market is projected to reach around USD 0.05 billion in 2026, representing roughly 0.6% of global revenues.

Competitive Landscape

Key Industry Players

Leading Companies Focus on Innovation and Product Launches to Maintain their Dominance

Diversified software portfolios and strategic initiatives are major factors contributing to the dominance of these companies in the market. GE HealthCare and Siemens Healthineers AG secured positions as major companies in the market in 2025. Furthermore, the increasing focus of key companies on launching innovative products to cater to the growing demand for advanced software is likely to strengthen their presence, further contributing to the global software as a medical device market share.

• For instance, in May 2026, Siemens Healthineers and Cercare Medical announced a global collaboration combining Cercare Medical NeuroSuite with Siemens’ Syngo DynaCT Multiphase for cone-beam CT perfusion-guided stroke treatment. The joint solution is CE-marked and FDA-cleared.

Other key players, including Medtronic, are also growing in the market, primarily due to their increasing emphasis on launching advanced software to strengthen their presence in the market.

List of Key Software as a Medical Device Companies Profiled

• Siemens Healthineers AG (Germany)
• GE HealthCare (U.S.)
• Brainlab SE (Germany)
• Koninklijke Philips N.V. (Netherlands)
• Elekta (Sweden)
• Heartflow, Inc. (U.S.)
• CANON MEDICAL SYSTEMS CORPORATION (Japan)
• FUJIFILM Corporation (Japan)
• RaySearch Laboratories (Sweden)
• RapidAI (U.S.)

KEY INDUSTRY DEVELOPMENTS

• May 2026: Brainlab SE, a global medtech company, announced that its Elements Spine Planning solution had received CE marking and was launched in the European Union. The AI-based software has been rolled out to expand the Brainlab Elements portfolio.
• March 2025: FUJIFILM Corporation, a provider of enterprise imaging and informatics solutions, collaborated with Amazon Web Services. Additionally, AWS has validated Fujifilm’s Synapse enterprise PACS, specifically Digital Pathology PACS, Cardiology PACS, Radiology PACS, and the Synapse VNA for cloud readiness, further expanding and strengthening cloud hosting capabilities for Fujifilm’s North American Synapse Enterprise Imaging customer base.
• May 2024: Elekta launched its latest linear accelerator, Evo, a CT-Linac with new high-definition AI-enhanced imaging, capable of delivering offline and online adaptive radiation therapy as well as improved standard image-guided radiation therapy treatments.
• April 2024: GE HealthCare acquired MIM Software Inc., adding MIM Software’s imaging analytics and digital workflow solutions as a part of its global medical technology, pharmaceutical diagnostics, and digital portfolio.
• October 2022: Heartflow, Inc., the company revolutionizing precision heart care, received U.S. Food and Drug Administration (FDA) 510(k) clearance on two AI-powered products: Plaque analysis and Roadmap analysis.

REPORT COVERAGE

The report provides a detailed global software as a medical device market analysis and examines leading companies and market segmentation, including SaMD risk category, deployment, clinical function, clinical specialty, and end user. Besides this, the global report offers insights into the market trends and highlights key industry developments. The report encompasses several factors that have contributed to the growth and advancement of the market over recent years.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation

Research Methodology

1. Bottom-Up Approaches

Approach 1:       Revenues and Market Share of Major SaMD Players

• Collect SaMD-attributable revenue from annual reports, SEC filings, investor presentations, earnings releases, and company product disclosures.
• Separate standalone regulated SaMD from embedded device software, hardware, general healthcare IT, implementation services, and other out-of-scope revenue.
• Map portfolios by clinical function, specialty, deployment, end user, and risk category; estimate revenue for private/diversified vendors using disclosed installed base, commercial footprint, and product mix.
• Cross-check pure-play benchmarks such as Heartflow and RaySearch, whose reported businesses are much closer to the study scope than diversified medtech vendors.
• Triangulate company totals against estimated total market and a long-tail residual to avoid overestimating large vendor shares.

Approach 2: Product-Level Usage, Installed Base, and Pricing

• Build a database of commercially available regulated SaMD products and classify them across the predefined market segmentation.
• Collect hospital/customer counts, active users, scan/test/patient volumes, and annual software utilization wherever disclosed.
• Apply subscription, annual license, per-patient, per-scan, per-test, or per-analysis pricing ranges appropriate to product type and geography.
• Estimate product revenue as commercial volume × applicable software price and aggregate by company/region while excluding hardware/services.

Approach 3: Country-Level SaMD Spending and Adoption Model

• Anchor country demand to healthcare expenditure, digital health infrastructure, hospital capacity, diagnostic intensity, and technology adoption.
• Adjust for country regulatory maturity, reimbursement, cloud readiness, and commercialization depth rather than assuming a uniform share of health spending.
• Use country-specific adoption factors so Germany, the U.K., Japan, and other mature markets can grow below faster emerging countries when evidence supports the pattern.
• Aggregate country estimates to region and global totals and reconcile them with vendor and product-level approaches.

2. Top-Down Approaches

Approach 1:  Analysis of Parent Addressable Medical Software & Digital Health Spending

• Estimate the broader medical software and digital-health spending pool by country.
• Identify the share attributable specifically to regulated standalone SaMD.
• Adjust for digital-health adoption, hospital IT maturity, cloud penetration, reimbursement, and regulatory approvals.
• Exclude EHR/EMR, general healthcare IT, embedded software, hardware, telehealth-only platforms, and non-medical wellness apps.
• Cross-check the estimate with company revenues, product-level usage/pricing, and regulatory product counts.
• Aggregate country estimates to derive regional and global market size.

3. List of Key Sources

• Company annual reports, SEC filings, investor presentations, and official product pages
• FDA
• IMDRF
• European Commission / MDR / IVDR / MDCG
• PMDA / MHLW
• NMPA
• CDSCO
• TGA
• Health Canada
• WHO
• OECD
• World Bank
• Eurostat
• CMS
• NICE / NHS England
• BfArM / G-BA
• ClinicalTrials.gov
• Peer-reviewed journals and official hospital deployment announcements

4. Primary Interviews

Supply-Side Interviews: 60%

• Key Respondents:
• SaMD developers and product management leaders
• Business-development, partnership and commercial executives
• Regulatory affairs, quality and market access professionals
• Clinical affairs and real-world evidence leaders
• AI/data science and cybersecurity leaders
• Hospital implementation, integration, and customer-success teams

Demand-Side Interviews: 40%

• Key respondents:
• Specialist clinicians in cardiology, neurology, ophthalmology, radiology, and behavioral health
• Hospital CIO/CDO/CMIO and digital health leaders
• Diagnostic-center and laboratory directors
• Hospital procurement and value analysis teams
• Payers, reimbursement specialists, and HTA experts
• Clinical IT, cybersecurity, and interoperability leaders